Published in Arterioscler Thromb Vasc Biol on December 01, 2010
Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis (2012) 1.00
Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorldJournal (2014) 0.90
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
The genetics of common variation affecting platelet development, function and pharmaceutical targeting. J Thromb Haemost (2011) 0.82
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
Genomewide association analysis of coronary artery disease. N Engl J Med (2007) 24.38
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med (1994) 7.47
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood (2002) 4.72
PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet (1997) 4.27
A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med (1996) 3.72
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation (2010) 3.68
Genetic and environmental influences on premature death in adult adoptees. N Engl J Med (1988) 3.63
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood (2009) 2.64
Integrin binding and mechanical tension induce movement of mRNA and ribosomes to focal adhesions. Nature (1998) 2.61
Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation (2001) 2.54
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol (2007) 2.36
Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics (2003) 2.25
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
The control of mRNA production, translation and turnover in suspended and reattached anchorage-dependent fibroblasts. Cell (1978) 2.19
Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet (2010) 1.97
Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A (1998) 1.97
Class prediction models of thrombocytosis using genetic biomarkers. Blood (2009) 1.92
Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation (2000) 1.91
Messenger RNA profiling of human platelets by microarray hybridization. Thromb Haemost (2003) 1.87
A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood (2009) 1.85
A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet (2008) 1.81
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation (2003) 1.79
Aggregometry detects platelet hyperreactivity in healthy individuals. Blood (2005) 1.73
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol (2006) 1.60
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol (2001) 1.57
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol (2009) 1.57
Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet (1999) 1.54
VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. J Thromb Haemost (2009) 1.54
Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study. Circ Cardiovasc Genet (2009) 1.51
Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood (1998) 1.51
Miniaturization in functional genomics and proteomics. Nat Rev Genet (2005) 1.44
Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 1.44
Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. Atherosclerosis (1998) 1.42
Effects of platelet membrane glycoprotein polymorphisms on the risk of myocardial infarction in young males. Isr Med Assoc J (2002) 1.39
Association of genetic polymorphisms in the fibrinogen and platelet glycoprotein genes with unstable angina in Chinese patients. Clin Cardiol (2004) 1.39
Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost (2007) 1.37
Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem (2005) 1.34
Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J (2007) 1.31
A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol (2008) 1.29
Aggregation of coronary risk factors in families of men with fatal and non-fatal coronary heart disease. Br Heart J (1979) 1.26
Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood (1997) 1.23
Can we override clopidogrel resistance? Circulation (2009) 1.18
A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med (2003) 1.15
Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. Thromb Haemost (2005) 1.14
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. Blood (2004) 1.11
The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease. Blood (2003) 1.08
Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost (2001) 1.07
Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting. Blood (2000) 1.06
Proteomic approaches to dissect platelet function: Half the story. Blood (2006) 1.05
Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood (1998) 1.04
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J (2009) 1.03
Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol (2001) 1.03
Platelet genomics and the risk of atherothrombosis. J Thromb Haemost (2007) 0.99
Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood (1999) 0.98
The genetics of normal platelet reactivity. Blood (2010) 0.98
Platelet glycoprotein I(b)alpha and integrin alpha2 beta1 polymorphisms: gene frequencies and linkage disequilibrium in a population diversity panel. J Thromb Haemost (2005) 0.96
Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke (2000) 0.95
PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation (1999) 0.94
Platelet GP IIIa PlA and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol (1998) 0.93
Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart (2002) 0.93
Transcript profiling of human platelets using microarray and serial analysis of gene expression (SAGE). Methods Mol Biol (2009) 0.93
Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. Br J Haematol (2001) 0.92
Polymorphisms in platelet glycoprotein 1balpha and factor VII and risk of ischemic stroke: a meta-analysis. Stroke (2008) 0.92
Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke (2001) 0.91
A combined genome-wide linkage and association approach to find susceptibility loci for platelet function phenotypes in European American and African American families with coronary artery disease. BMC Med Genomics (2010) 0.91
Multivariate QTL linkage analysis suggests a QTL for platelet count on chromosome 19q. Eur J Hum Genet (2004) 0.91
The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol (2002) 0.90
Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol (2000) 0.89
Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. Blood (2001) 0.87
Platelet glycoprotein receptor IIIa polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study. Stroke (1998) 0.85
Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol (2003) 0.85
von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol (2003) 0.83
Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation (2000) 0.83
Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost (1998) 0.82
Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Br J Haematol (1999) 0.82
Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis (2002) 0.82
Polymorphisms of platelet adhesive receptors: do they play a role in primary intracerebral hemorrhage? Cerebrovasc Dis (2003) 0.81
Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol (2000) 0.81
Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis (2007) 0.81
Epinephrine-induced platelet aggregation. A twin study. Clin Genet (1984) 0.80
Platelet glycoprotein Ibalpha polymorphisms modulate the risk for myocardial infarction. Thromb Haemost (2004) 0.80
Twin research in coronary heart disease. Prog Clin Biol Res (1981) 0.80
Polymorphisms of platelet glycoproteins in relation to macrovascular disease in type 2 diabetes mellitus. Diabet Med (1998) 0.80
The glycoprotein Ib/IX complex regulates cell proliferation. Blood (1999) 0.79
Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function--effect in thromboembolic diseases. Thromb Haemost (1999) 0.79
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet (2008) 12.43
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood (2002) 4.72
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med (2004) 3.69
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol (2013) 3.43
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. Circulation (2013) 2.85
Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84
Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol (2011) 2.83
Avoiding the high Bonferroni penalty in genome-wide association studies. Genet Epidemiol (2010) 2.79
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation (2003) 2.70
Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv (2009) 2.64
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA (2011) 2.57
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 2.52
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest (2008) 2.46
Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol (2011) 2.44
Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48. Nat Genet (2012) 2.43
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40
Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood (2008) 2.36
Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med (2005) 2.32
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J (2011) 2.31
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2014) 2.30
Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
Evolution of the coronary care unit: clinical characteristics and temporal trends in healthcare delivery and outcomes. Crit Care Med (2010) 2.19
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA (2005) 2.17
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 2.12
A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes (2011) 2.09
Molecular basis of restenosis and drug-eluting stents. Circulation (2005) 2.08
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol (2007) 2.03
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
Impact of a community-based multiple risk factor intervention on cardiovascular risk in black families with a history of premature coronary disease. Circulation (2005) 2.03
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation (2007) 2.03
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol (2010) 2.00
Metabolic signatures of exercise in human plasma. Sci Transl Med (2010) 1.99
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke (2013) 1.99
Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet (2010) 1.97
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol (2005) 1.97
Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.97
Hemizygous deficiency of Krüppel-like factor 2 augments experimental atherosclerosis. Circ Res (2008) 1.94
Class prediction models of thrombocytosis using genetic biomarkers. Blood (2009) 1.92
KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet (2003) 1.90
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol (2003) 1.89
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J (2008) 1.88
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging (2012) 1.85
Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv (2011) 1.85
Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation (2009) 1.84
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet (2010) 1.79